Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability and Food Effect of BMS-986419 IR Tablet in Healthy Adults
NCT05963932Phase 1Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Aug 2023
- Primary completion
- Oct 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of BMS-986419 in Alzheimer's disease (AD) and amyotrophic lateral sclerosis (ALS) (4 arms), sponsored by Bristol Myers Squibb. Primary endpoints: Maximum observed plasma concentration up to 15 days, Area under the plasma concentration-time curve from time zero to last quantifiable concentration up to 15 days and 1 more. Started Aug 2023; status: completed.
02
Drugs
BMS-986419
03
Conditions
Alzheimer's disease (AD)amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on NCT05963932.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05963932.